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Objective. Until recently, advancedmedullary thyroid cancer (MTC) had few treatment options except surgery.ThemTOR inhibitor
everolimus has shown encouraging results in neuroendocrine tumors. As part of a prospective phase II study, we analyzed the safety
and efficacy of everolimus in advanced MTC. Methods. Seven patients with per RECIST 1.1 documented advanced MTC were
included and received everolimus 10mg daily. The primary objective was determining treatment efficacy. Secondary endpoints
included progression-free survival (PFS), overall survival (OS), toxicity, and pharmacokinetics (PK). Results. Median follow-up
duration was 28 weeks (17–147). Five patients (71%) showed SD, of which 4 (57%) showed SD >24 weeks. Median PFS and OS were
33 (95%CI: 8–56) and 30 (95%CI: 15–45) weeks, respectively. Toxicity was predominantly grade 1/2 and included mucositis (43%),
fatigue (43%), and hypertriglyceridemia (43%). FourMTCs harbored the somatic RETmutation c.2753T>C, p.Met918Thr.The best
clinical response was seen in aMEN2Apatient. PK characteristics were consistent with phase I data. One patient exhibited extensive
toxicity accompanying elevated everolimus plasma concentrations.Conclusions.This study suggests that everolimus exerts clinically
relevant antitumor activity in patients with advanced MTC. Given the high level of clinical benefit and the relatively low toxicity
profile, further investigation of everolimus in these patients is warranted.
1. Introduction
Medullary thyroid cancer (MTC) is a neuroendocrine tumor
derived from the calcitonin-producing thyroid C cells and
accounts for 3–5% of cases of thyroid cancer [1]. Until
recently, besides surgery few curative and palliative treatment
options were available for patients with MTC. Conventional
treatment modalities have disappointing outcomes in most
patients with MTC, indicating the need for new treatments.
The American Thyroid Association therefore recom-
mends that these patients should be enrolled in clinical trials.
Concurrently, an increased understanding of thyroid tumori-
genesis has led to the identification of potential targets, with
novel therapeutic agents now able to target these biological
abnormalities.
In addition, many genetic alterations affecting tyrosine
kinase signaling pathways have recently been identified in
various forms of thyroid cancer such as the activating RET
mutations present in >95% of hereditary MTC and in 20–
50% of sporadic MTC [2, 3]. The phosphatidylinositol-3-
kinase (PI3K)/Akt pathway regulates cell growth, prolifer-
ation, and survival in all thyroid tumor subtypes [4]. An
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important effector in the PI3K/Akt pathway is the mam-
malian target of rapamycin (mTOR). Activation of themTOR
serine/threonine protein kinase has been reported in a variety
of malignant tumors, including thyroid tumors, with an
estimated 70% of all tumors showingmTORupregulation [5].
As a result of this accrued understanding of the bio-
logical basis of thyroid cancer development, several clinical
trials with multitarget tyrosine kinase inhibitors (TKIs) have
been conducted. Everolimus is an orally available deriva-
tive of rapamycin, targeting mTOR. Everolimus exerts its
activity through high affinity interaction with an intra-
cellular receptor protein, the immunophilin FKBP12. The
FKBP12/everolimus complex subsequently interacts with
the mTOR protein kinase, inhibiting downstream signaling
events involved in regulation of the G1 to S-phase transition
[6]. The use of everolimus in neuroendocrine tumors has
shown encouraging results, both in vitro and in vivo [7–9].
We initiated a phase II study to assess safety and
efficacy of everolimus on tumor progression in patients
with advanced thyroid carcinoma (THYRRAD, www
.clinicaltrials.gov CRAD001CNL08T). In addition, pharma-
cokinetic parameters were assessed. Here we present a
subgroup analysis of seven MTC patients.
2. Materials and Methods
2.1. Patients. Eligibility criteria were the presence of per
RECIST 1.1 (Response Evaluation Criteria in Solid Tumors)
documented progressivemetastatic or inoperableMTC in the
12 months prior to therapy [10]. Patients were required to be
≥ 18 years of age with a Karnofsky performance score > 70%.
Laboratory requirements consisted of adequate bonemarrow
function (absolute neutrophil count ≥ 1,500/𝜇L, platelets
≥100,000/𝜇L, and hemoglobin ≥ 5.6mm/L), liver function
(serum bilirubin ≤ 1.5x upper limit of normal (ULN) and
serumALT and AST ≤ 2.5x ULN), and renal function (serum
creatinine ≤ 2x ULN). Women of childbearing age were
required to have a negative serum or urinary pregnancy test
within 14 days prior to the first dose of the study drug. Patients
were not excluded based on number or type of prior therapies
received, with the exception of prior targeted therapy with
everolimus or other mTOR inhibitors.
Written informed consent was provided by all patients
before enrollment in the trial. The study protocol was
approved by the Institutional ReviewBoard of LeidenUniver-
sityMedical Center and performed in the university hospitals
of Leiden and Groningen. This study was registered at
ClinicalTrials.gov (#NCT01118065).
2.2. Study Design. We performed a nonrandomized, open-
label, multicenter, single arm phase II trial of everolimus
in patients with advanced thyroid cancer; 28 patients with
differentiated (DTC), 7 patients with anaplastic (ATC), and
7 patients with medullary (MTC) thyroid carcinoma were
included.The primary objective was to determine the efficacy
(response rate and stable disease >24 weeks) of everolimus.
Secondary objectives were determination of the maximum
percentage of tumor reduction for target lesions, describing
activity time to event endpoints, and assessment of toxicity,
adverse events (AEs), and pharmacokinetics. Eligibility
assessments, including a review of medical history and
prior treatments, physical examination, and disease staging
assessments were performed within 4 weeks prior to the first
dose of everolimus. Baseline evaluations, comprising perfor-
mance status, vital signs, and laboratory tests, were assessed
within 2 weeks prior to initiation of therapy. Everolimus was
administered at a dose of 10mg orally once daily until disease
progression, unacceptable toxicity, death, or patients’ own
request. Objective tumor response and time of progressions
were measured according to the RECIST criteria version 1.1
every 12 weeks (±2 weeks) during the first year, thereafter
every 6 months and at study discontinuation.
Safety assessments were made every 4 weeks by adverse
event collection, standard clinical and laboratory tests, and
physical examinations. In case of toxicity or AEs requiring
dose adjustments, drug dosing was interrupted or modified
according to the guidelines. AEmonitoringwas continued for
at least 4 weeks following the last dose of study treatment.The
incidence, grade, and casual relationship of adverse events
were graded with the use of Common Terminology Criteria
for Adverse Events (CTCAE, version 4.0). Following study
discontinuation, all patients were followed for survival for 4
weeks.
2.3. Laboratory Parameters. Serum thyroid stimulating hor-
mone (TSH), free thyroxine (T4), carcinoembryonic antigen
level (CEA), calcitonin, and safety parameters were assessed
at all visits. Safety parameters included a total blood count
as well as serum levels of sodium, potassium and creatinine,
lipids, coagulation, and renal and liver function.
2.4. Somatic Mutation Spectrum Screening. DNA for muta-
tion analysis was available for six MTC tumors. Somatic
hotspot mutations were identified using a custom AmpliSeq
panel that targets somatic hotspot mutations in 22 genes
using Ion Torrent AmpliSeq sequencing chemistry (Life
Technologies, Foster City, CA, details available on request).
The samples were sequenced using the Ion Torrent PGM
(Life Technologies, FosterCity, CA). FastQ sequence data files
from the Ion Torrent PGM were analyzed with NextGENe
software (version v.2.3.4.2, Softgenetics, State College, PA)
using standard settings for somaticmutation analysis, exclud-
ing known polymorphisms.
2.5. Pharmacokinetics. In order to measure blood concen-
tration levels of everolimus and assess everolimus steady-
state pharmacokinetics (PK), patients were admitted to hos-
pital for PK sampling on day 15 of each treatment cycle.
Samples were collected in EDTA tubes at predose and at
1, 2, and 3 hours after everolimus intake. Additional PK
sampling at 4, 5, 6, 7, and 8 hours after everolimus intake
was optional. Everolimus concentrations in whole blood
were determined using a validated Ultra Performance Liq-
uid Chromatography-Tandem Mass Spectrometric (UPLC-
MS/MS) assay. Pharmacokinetic parameters were calcu-
lated with a noncompartmental approach using WinNonLin
and included the area under the concentration time curve
over the dosing interval (AUC0–24 hr), trough everolimus
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concentration (𝐶trough), time to reach peak concentration
(𝑇max), peak concentration (𝐶max), and the elimination half-
life (𝑇
1/2
).
2.6. Statistical Analysis. Seven MTC patients were analyzed
as a separate cohort for response rate. If no responses
were present in this patient group, we could conclude
that further investigation of everolimus in MTC patients is
unwarranted. Endpoints were reported as median (range)
or proportions. Estimates of progression-free survival (PFS)
(time from starting study drug to progression or death,
whichever occurred first) and OS (time from starting study
drug to the date of death by any cause), with associated
95% CIs, were obtained using the Kaplan-Meier method.
Patients who were progression-free and/or alive at the time
of data analysis were censored. Variables influencing the
response to everolimus were analyzedwith binominal logistic
regression. The calculations were performed using SPSS 20.0
for Windows (SPSS, Chicago, IL, USA).
3. Results
3.1. Patient Characteristics. All 7 patients withmedullary thy-
roid carcinoma were included in this efficacy and tolerability
analysis. The follow-up of the study ended on December
31, 2013, with a median follow-up of 28 weeks (range 17–
145 weeks). The median everolimus treatment period was
17 weeks (range 6–116 weeks). One patient was still on
everolimus treatment at the time follow-up ended.
Baseline characteristics are listed in Table 1. Two (29%)
females and 5 (71%) males were included, with a median age
of 53 years (range 44–74). At study entry, 1 (14%) patient had
locally advanced disease, while the other 6 (86%) had distant
metastasis. None of the patients were treatment na¨ıve.
3.2. Efficacy. Efficacy analysis showed promising results. Five
patients (71.4%) showed stable disease (SD), with 4 (57.1%)
having SD lasting >24 weeks. Median SD duration was 24
weeks (range 17–117weeks). At the time of data analysis (31-12-
2013), 1 patient still had ongoing SD.There were no complete
(CR) or partial (PR) responses. Data on efficacy are given in
Table 2 and Figure 1.
Estimated median PFS was 33 weeks (95% CI: 8–56
weeks). The median overall survival (OS) was 30 weeks (95%
CI: 15–45 weeks). Disease progression and survival appeared
not to be influenced by age, gender, disease site, mutational
status, everolimus blood concentration, or dose reduction.
Changes in calcitonin andCEAcould not be related to clinical
outcome, as demonstrated in Table 3 and Figure 2.
3.3. Toxicity. Three patients (43%) required dose reduction
due to toxicity. One patient (14%) discontinued the study
after 12 weeks due to complaints of fatigue and peripheral
edema. All observed AEs are listed in Table 4. Treatment-
related AEs were predominantly grade 1 or 2, with the most
common events including mucositis, fatigue, and hyper-
triglyceridemia. Grade 3 AEs consisted of fatigue (29%),
peripheral edema (14%), hypercholesterolemia (14%), hyper-
glycemia (14%), pneumonia (14%), and pneumonitis (14%).
Table 1: Baseline characteristics.
All patients
(𝑛 = 7)
Gender (𝑛, %)
Female 2 (29)
Male 5 (71)
Age (year; median, range) 53 (44–74)
Time from diagnosis (year; median, range) 4.3 (1.6–25.6)
Initial TNM stage (𝑛, %)
IB (T2 N0 M0) 0
IIB (T2-3 N0-1 M0) 2 (29)
IIIA (T1-3 N1-2 M0) 3 (43)
IV (any T any N M1) 2 (29)
Unknown 0
Tumor extent at study entry (𝑛, %)
Locally advanced 1 (14)
Metastatic 6 (86)
Number of disease sites (𝑛, %)
1 1 (14)
2 2 (29)
≥3 4 (57)
Mutational status (𝑛, %)
RET M918T 4 (57)
MEN-IIA 1 (14)
EGFR P848L 1 (14)
Unknown 1 (14)
Prior treatment (𝑛, %)
Surgery 6 (86)
Radiation therapy 2 (29)
Tyrosine kinase inhibitorx∘ 4 (57)
x3 patients received XL184; 1 patient showed an ongoing PR for 14 months
before he became progressive; 2 had PD as best result after 12 and 24 weeks.
∘1 patient had vandetanib for 8 months, followed by 3 months of sunitinib,
which was stopped due to side effects.
No grade 4 AEs were observed. One (14%) serious adverse
event (SAE)was reportedwhen a patientwas hospitalized due
to acute stomach pain after 5 weeks of everolimus treatment.
A gastroduodenoscopy revealed no abnormalities and the
complaints resolved spontaneously.Themajority of AEs were
controllable with dose reduction, medication, or supporting
measures. There appeared to be no relation between toxicity
and performance state or age.
One patient with relatively high everolimus blood
plasma concentrations (AUC0–24 hr, 960𝜇g∗hr/L), as shown
in Figure 3, also showed more profound toxicity. This patient
suffered a total of 13 AEs, whereas the median number of
AEs was 5 (range 3–13). Comedication and a high hematocrit
were excluded as possible causes of the higher plasma
concentrations in this patient.
3.4. Mutation Analysis. One of the 7 MTC patients was
excluded from the mutation analysis because no tumor tissue
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Figure 1: Kaplan-Meier curves of (a) overall survival and (b) median progression-free survival.
Table 2: Efficacy analysis.
Parameter
Median duration of treatment (weeks; range) 17 (6–116)
Cumulative dose of everolimus (mg; median,
range) 1200 (440–8012)
Median duration of follow-up (weeks; range) 28 (17–147)
Best response by RECIST 1.0 (𝑛, %)
Complete response 0 (0)
Partial response 0 (0)
Stable disease 5 (71)†
Progressive disease 2 (29)
Overall disease control 5 (71)
Median duration of SD (weeks; range) 24 (17–116)‡
Median PFS (weeks; 95% CI) 33 (8–56)
Median OS (weeks; 95% CI) 30 (15–45)
RECIST: Response Evaluation Criteria in Solid Tumors, SD: stable disease,
PFS: progression-free survival, and OS: overall survival.
†4 of 5 patients showed SD >24 weeks; ‡at time of data analysis, 1 patient still
had ongoing SD.
was available. Of the 6 remaining patients, one MEN2A
patient carried a germline RET c.1858T>C, p.Cys620Arg
mutation. Using targeted nextgen sequencing of tumors,
four showed a somatic RET c.2753T>C, p.Met918Thr
mutation, including one that also carried an EGFR
c.2543C>T, p.Pro848Leu mutation (see supplementary
Table 1 in Supplementary Material available online at
http://dx.doi.org/10.1155/2015/348124). It is noteworthy that
the MEN2A patient showed the best response to everolimus
treatment, with the longest period of stable disease.
3.5. Pharmacokinetics. One patient completed only the short
PK sampling schedule; all other patients participated in the
extended sampling schedule up to 8 hours after everolimus
intake. Individual everolimus concentrations versus time
profiles are shown in Figure 3.
A summary of everolimus pharmacokinetics is shown
in Table 5. The median (range) AUC0–24 hr for everolimus
was 421𝜇g∗hr/L (257–960𝜇g∗hr/L) and the median 𝐶trough
was 7.4𝜇g/L (4.0–18.3 𝜇g/L). The median 𝑇max was 1.0 hour
and the median 𝐶max was 48.2 𝜇g/L. The median 𝑇1/2 of
everolimus was 13.8 hours (10.9–32.4 hr).
4. Discussion
Until recently, surgerywas accompanied by only limited cura-
tive and palliative treatment options for patients with MTC,
emphasizing the need for new therapies. Using everolimus,
a significant dose-dependent inhibition in cell proliferation
was observed in two medullary thyroid cancer cell lines [11].
Everolimus significantly inhibited cell viability in a dose- and
time-dependent fashion and diminished phosphorylation of
mTOR in a TT thyroid cancer cell line and cultured human
MTCs [12]. Two case reports comprising three patients
with advanced MTC showed beneficial effects of everolimus
[11, 13]. Recently, a phase II study in patients treated with
everolimus, with advanced thyroid cancer of all histologic
subtypes (𝑛 = 38), reported a partial response (PR) and stable
disease (SD) in 5% and 76% of patients, respectively. Median
progression-free survival (PFS) was 47 weeks [14].
Our phase II trial on advanced MTC showed promising
results, with stable disease in 5 of 7 (71%) patients. The
median PFS andOSof 33 and 30weeks, respectively, were also
promising. The lack of PRs is easily explained by the fact that
these tumors are slowly progressive and PRs were therefore
not expected. Due to the fact that only seven patients were
included,wewere not able to identify parameters significantly
influencing response or survival. Although several trials have
reported a biochemical CEA and calcitonin response that
International Journal of Endocrinology 5
Table 3: Changes in calcitonin and CEA during treatment.
Patient Level at baseline Maximum reduction (%) Level at study exit
Increase from
baseline
till study exit (%)
Best response
1 CT (pmol/L) 73900 — 77700 105,1 SD
CEA (𝜇g/L) 246,5 — 353,3 143,3
2 CT (pmol/L) 245 — 280 114,3 SD
CEA (𝜇g/L) 354,3 — 2208,0 623,2
3 CT (pmol/L) 6750 — 29800 441,4 PD
CEA (𝜇g/L) 1477,0 — 2081,0 140,9
4 CT (pmol/L) 12716 30,3 8869 ‡ PD
CEA (𝜇g/L) 216,9 4,9 247,9 114,3
5 CT (pmol/L) 680 37,3 1148 168,8 SD
CEA (𝜇g/L) 117,1 — 164,4 140,4
6 CT (pmol/L) 58 56,9 89 153,4 SD
CEA (𝜇g/L) 70,7 35,5 86,7 122,6
7 CT (pmol/L) 2156 — 5239
+ 243+ SD
CEA (𝜇g/L) 91,1 10,1 166,7+ 183+
CT: calcitonin and CEA: carcinoembryonic antigen level.
—: therewas no reduction inCTorCEA compared to baseline and ‡: therewas no increase inCT compared to baseline; +patient is still on everolimus treatment.
Table 4: Adverse events.
Event
All Grades number of patients (% of category)
Number of patients
(% of total (𝑛 = 7)) 1 2 3 4
Mucositis 3 (43) 2 (67) 1 (33)
Fatigue 3 (43) 1 (33) 2 (67)
Hypertriglyceridemia 3 (43) 1 (33) 2 (67)
Peripheral edema 2 (29) 1 (50) 1 (50)
Anorexia 2 (29) 2 (100)
Diarrhea 2 (29) 1 (50) 1 (50)
Rash 2 (29) 1 (50) 1 (50)
Pneumonia 2 (29) 1 (50) 1 (50)
Liver function disorders 2 (29) 1 (50) 1 (50)
Hypercholesterolemia 2 (29) 1 (50) 1 (50)
Hypophosphatemia 2 (29) 2 (100)
Hypoparathyroidism 2 (29) 2 (100)
Weight loss 1 (14) 1 (100)
Nausea 1 (14) 1 (100)
Vomiting 1 (14) 1 (100)
Constipation 1 (14) 1 (100)
Allergic reaction 1 (14) 1 (100)
Dry skin 1 (14) 1 (100)
Itch 1 (14) 1 (100)
Asthenia 1 (14) 1 (100)
Anemia 1 (14) 1 (100)
Hyperglycemia 1 (14) 1 (100)
Cough 1 (14) 1 (100)
Dyspnea 1 (14) 1 (100)
Pneumonitis 1 (14) 1 (100)
All AEs graded according to Common Terminology Criteria for Adverse Events version 4.0.
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Figure 2: Serum calcitonin and CEA concentrations per patient over time. (a) Serum calcitonin over time for all patients, (b) close-up of
figure (a) for patients 2, 5, and 6, (c) serum CEA for all patients, and (d) close-up of figure (c) for patients 1, 4, 5, 6, and 7.
reflects the radiological response, these changes were not
always significant in our study andwewere unable to confirm
this correlation [11, 14–16].
Although EGFR overexpression is frequently seen in
medullary thyroid cancer, EGFR mutations are rarely
described [17]. The EGFR P848L mutation we identified is
situated close to the L858R mutation, a well-known target in
nonsmall cell lung cancer. However, the P848L mutation has
been described in patients with nonsmall cell lung carcinoma
and is thought to be a functionally silent polymorphism,
insensitive to gefitinib treatment [18, 19].
TheMEN2AMTCpatient showed the best response upon
everolimus therapy. Apart from the treatment effect, the RET
c.1858T>C, p.Cys620Argmutation has been associated with a
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Figure 3: Individual observed concentration versus time profiles for
everolimus.
Table 5: Summary of everolimus pharmacokinetic parameters.
Median (range) Mean SD CV%
AUC
0–24 hr (𝜇g∗hr/L) 421 (257–959) 442 246 55.7%
𝐶trough (𝜇g/L) 7.4 (4–13.8) 9.0 5.2 57.8%
𝑇max (hr) 1 (0.33–3.08) 1.2 0.9 75.0%
𝐶max (𝜇g/L) 48.2 (37.8–102.3) 59.4 23.8 40.1%
𝑇
1/2
(hours) 13.8 (10.9–32.4) 16.5 7.5 45.5%
AUC is area under the concentration time curve, 𝐶max is peak plasma
concentration, CV% is coefficient of variation, SD is standard deviation, and
𝑇max is time to reach peak plasma concentration.
less aggressive phenotype compared to otherMEN2A-related
mutations such as the c.2753T>C p.Met918Thr mutation or
one of the classic mutations in exon 11 at codon 634 [20].
To the best of our knowledge, this is the first report of
administration of everolimus to a MEN2A patient.
Everolimuswas generally well tolerated, with themajority
of AEs being manageable and similar to previously reported
toxicities [14, 21]. The PK characteristics were also con-
sistent with phase I pharmacokinetic studies investigating
everolimus (10mg once daily) in solid and hematological
malignancies [22–24]. The interpatient variability in PK was
also comparable to previous research. Although based on
the short sampling schedule, the patient with the highest
exposure also showed the most extensive toxicity profile,
perhaps related to higher everolimus plasma concentrations.
Although everolimus treatment has shown encouraging
results in patients with a variety of solid tumors, it has to
be noted that its inability to inhibit mTORC2 may imply
an inability to achieve a potent and long term antitumor
effect. Hisamatsu et al. showed that simultaneous inhibi-
tion of mTORC2 during everolimus treatment enhanced
the antitumor effect of everolimus and prevented clear cell
carcinoma cells of the ovary from acquiring resistance to
RAD001 [25]. Furthermore, several reports have been pub-
lished describing a feedback loop between the mTOR path-
way and RAS/MAPK/ERK signaling, leading to activation
of a different prosurvival signaling pathway upon mTOR
inhibition.This mechanism of action suggests that treatment
with everolimus as a single molecular target agent may not be
sufficient, emphasizing the interest of studies with everolimus
combined with other targeted agents [6, 14, 26].
In conclusion, given the high rate of clinical benefit
and the relatively low toxicity profile found in this MTC
subgroup analysis, we believe that further investigation in
larger cohorts of MTC patients is now warranted, using
everolimus either as a single agent or in sequential or
combination therapy.
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